Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12393191 | 0.82 | CTSK (0.44) | CTSKMLYCDCHRM2CHRM4CHRM5 | |
| SCHEMBL13223495 | 0.81 | HDAC4 (0.37) | MLYCDHDAC4CHRM2CHRM4CHRM5 | |
| SCHEMBL8588152 | 0.80 | CTSK (0.39) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL24596804 | 0.79 | CTSK (0.41) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12393190 | 0.78 | CTSK (0.46) | CTSKMLYCDCHRM2CHRM4CHRM5 | |
| SCHEMBL24634228 | 0.76 | RIPK1 (0.45) | MLYCD | |
| SCHEMBL8436864 | 0.76 | CTSK (0.37) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL17801996 | 0.76 | MEN1 (0.41) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8434418 | 0.76 | MAPT (0.43) | CTSKMLYCDHDAC4CHRM2CHRM4 | |
| SCHEMBL8366044 | 0.76 | CTSK (0.41) | CTSKMLYCDCHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| WO-2022147223-A2 | 2'-MODIFIED NUCLEOSIDE BASED OLIGONUCLEOTIDE PRODRUGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | CTSK 551/4885MLYCD 4067/4885HDAC4 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.